Vorsicht ist insbesondere dann geboten, wenn Sie ein älterer Patient oder geschwächt sind.Wenden Sie dieses Arzneimittel nicht bei Kindern und Jugendlichen unter 18 Jahren an. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. 300 mg and 400 mg dual chamber syringe . Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. : Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, have been reported in clinical trials of elderly patients with dementia-related psychosis treated with oral aripiprazole. : Dosage adjustments are recommended in patients who are CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days. : ABILIFY MAINTENA should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold. If antipsychotic treatment is withdrawn, TD may remit, partially or completely. : Use ABILIFY MAINTENA with caution in patients who may experience conditions that increase body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics). The clinical trial was a 52-week, double-blind, placebo-controlled, randomized withdrawal trial in adults with BP-I aged 18 to 65 years, who were stabilized with Abilify Maintena prior to randomizationAbilify Maintena (aripiprazole) for extended-release injectable suspension is an atypical antipsychotic for intramuscular use. 300 mg and 400 mg vial . https://www.nami.org/Learn-More/Mental-Health-Conditions/Bipolar-Disorder. Abilify Maintena was approved in the U.S. in 2013 for the treatment of adults with schizophreniaThe most commonly observed adverse reactions with Abilify Maintena in patients with schizophrenia (incidence of 5 percent or greater and aripiprazole incidence at least twice that for placebo) were increased weight, akathisia, injection site pain, and sedationBP-I is a chronic mental illness with a 12-month and lifetime prevalence of 1.5% and 2.1%, respectivelyINDICATIONS and IMPORTANT SAFETY INFORMATION for ABILIFY MAINTENA® (aripiprazole)ABILIFY MAINTENA is an atypical antipsychotic indicated for:•               Treatment of schizophrenia in adults•               Maintenance monotherapy treatment of bipolar I disorder in adultsWARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy. : Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics. Die Injektionen werden nicht intravenös gegeben.Dieses Arzneimittel wird Ihnen unter ärztlicher Aufsicht verabreicht; es ist daher unwahrscheinlich, dass bei Ihnen zu viel angewendet wird. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability. For more information about Abilify Maintena, please visit: The phase III clinical trial supporting regulatory approval demonstrated the efficacy and safety of Abilify Maintena in the maintenance monotherapy treatment of BP-I. : Known hypersensitivity reaction to aripiprazole. Er/Sie wird mit Ihnen besprechen, wie diese Symptome kontrolliert oder eingedämmt werden können.Malignes neuroleptisches Syndrom (ein Syndrom mit Symptomen wie Fieber, Muskelsteifheit, schnelleres Atmen, Schwitzen, verringertes Bewusstsein und plötzliche Veränderungen des Blutdrucks und der Herzfrequenz).Serotoninsyndrom (eine Reaktion, die zu Glücksgefühlen, Benommenheit, Schwerfälligkeit, Rastlosigkeit, dem Gefühl betrunken zu sein, Fieber, Schwitzen oder steifen Muskeln führen kann)Herzprobleme, einschließlich Torsades de Pointes, Herzstillstand, Herzrhythmusstörungen, die auf anormale Nervenimpulse im Herzen zurückzuführen sein könnten, anormale Messwerte während der Herzuntersuchung (EKG), QT-VerlängerungSymptome, die mit Blutgerinnseln in den Venen, insbesondere in den Beinen, zusammenhängen (zu den Symptomen gehören Schwellungen, Schmerzen und Rötungen im Bein), die durch die Blutgefäße in die Lunge gelangen und Schmerzen in der Brust und Atembeschwerden verursachen könnenversehentliches Inhalieren von Nahrung mit Gefahr einer LungenentzündungGelbsucht (Gelbfärbung der Haut und der weißen Teile der Augen)Muskelschwäche, Empfindlichkeit oder Schmerzen in den Muskeln, insbesondere bei gleichzeitigem Auftreten von Unwohlsein, hoher Temperatur oder dunklem Urin.